A recent cover issue of Oncotarget, entitled, “Inhibitory effects of Tomivosertib in acute myeloid leukemia, was written by researchers from Northwestern University and Jesse Brown Veterans Affairs Medical Center. In this article, the authors assessed the therapeutic potential of tomivosertib, a highly selective MNK1/2 inhibitor. Findings from in vitro and mass spectrometry studies demonstrate potent anti-leukemic properties of tomivosertib, supporting further investigation of this drug as treatment for AML.